PRO-067

PRO-067 is a small molecule ophthalmic solution developed by Laboratorios Sophia for the treatment of eye diseases, specifically targeting primary open-angle glaucoma and ocular hypertension. It was designed as a hypotensive therapy to lower intraocular pressure (IOP), with clinical studies aiming to demonstrate its non-inferiority compared to GAAP Ofteno (latanoprost 0.005%). The drug reached phase 3 clinical trials but development was ultimately discontinued. Its mechanism of action is presumed similar to latanoprost, which acts as a prostaglandin F2α analog increasing uveoscleral outflow, though the precise target for PRO-067 is not explicitly stated in available sources[1][3][9].